08:00 , Dec 13, 2010 |  BC Week In Review  |  Company News

Axis-Shield, Catch Inc. deal

Axis-Shield acquired Catch's global clinical chemistry homocysteine business for $10 million in cash. Catch also is eligible for royalties of up to 10% of homocysteine enzymatic revenues. Axis-Shield said the acquisition would increase its competitiveness...
07:00 , Oct 25, 2004 |  BC Week In Review  |  Company News

Axis-Shield sales and marketing update

ASD launched a homocysteine assay that allows laboratories to perform homocysteine testing on automated clinical chemistry systems. The test is based on technology ASD licensed from Catch Inc. (Bothell, Wash.). Homocysteine is a marker for...
07:00 , Jun 7, 2004 |  BC Week In Review  |  Company News

Axis-Shield, Beckman Coulter, Catch Inc. sales and marketing update

BEC will market reagents from Catch for use on its Synchron clinical chemistry analyzers. Under a recent homocysteine patent settlement with Catch, ASD will receive royalties on all tests sold by Catch. Axis-Shield plc (LSE,...